Brief introduction to the instructions for use of giritinib (segatan)

Giritinib (trade name: Segatan), as a drug specifically designed to carry FMS-like tyrosine kinase3 (< Targeted therapeutic drugs designed for patients with acute myeloid leukemia (AML) with mutations in span>FLT3 have brought new treatment hope to many patients. To ensure patients can use giritinib safely and effectively, the following is a concise guide to its use.

1. Applicable objects

Giritinib is particularly suitable for adult patients with relapsed or refractory AML confirmed to carry FLT3 mutations through rigorous genetic testing. Before starting treatment, patients must pass genetic testing to determine if they are candidates for the drug.

2. Medication guidance

1. Dosage recommendations: The recommended starting dose of giritinib is 120mg (mg), that is, 3 tablets of 40mg should be taken in one sitting. In the absence of disease progression or unacceptable toxicity, it is recommended to continue treatment for at least 6 months to ensure sufficient time for the drug to produce a clinical response. Patients should not adjust the dosage or stop taking the medicine without the guidance of a doctor.

2. How to take: Giritinib should be swallowed whole and given with water. It should not be chewed, broken or crushed. Patients can choose to take it before or after meals, but it is recommended to take it at the same time every day to maintain stable blood concentrations.

3. Handling of missed doses: If the patient forgets to take a dose, he should take it as soon as he remembers. However, if it is less than 12 hours before the next dose, you should skip the missed dose and continue taking the next dose at the originally planned time.

1. Things to note

1. Gene testing: Before using giritinib, FLT3 gene testing must be performed to confirm whether the patient carries the mutation.

2. Monitoring indicators: During the treatment period, the patient's blood cell count, blood biochemical indicators and electrocardiogram should be regularly monitored in order to detect and deal with possible adverse reactions in a timely manner.

3. Special groups: Pregnant and lactating women should avoid using gilitinib, or use it with caution under the guidance of a doctor. Women of childbearing potential should use effective contraceptive measures during treatment.

4. Drug interactions: Giritinib is mainly metabolized by CYP3A4 enzyme, so it should be avoided to be used in combination with strong CYP3A/P- glycoprotein inducers or inhibitors to prevent drug interactions.

5. Storage conditions: Medications should be stored in their original containers at room temperature, away from moisture and heat sources.

4. Possible adverse reactions

Giritinib may cause a series of adverse reactions, including but not limited to muscle or joint pain, headache, dizziness, fever, fatigue, abnormal liver function and differentiation syndrome. Patients should pay close attention to their own symptoms during use and seek medical attention promptly if there are any abnormalities.

In summary, giritinib is an effective treatment for selectAML patients. Patients should fully understand its indications, usage, dosage and precautions before use, and use it rationally under the guidance of a doctor to ensure the safety and effectiveness of treatment. Currently, there are both original giritinib and affordable generic drugs available on the market. Patients should choose formal channels when purchasing and make choices based on their own needs.